健民集团（600976）8月25日主力资金净流出1814.90万元

Group 1 - The core viewpoint of the news is that Jianmin Group (600976) has shown a slight increase in stock price, but the company is experiencing a decline in revenue and net profit according to its latest financial report [1][3] - As of August 25, 2025, Jianmin Group's stock closed at 41.52 yuan, with a trading volume of 54,600 lots and a transaction amount of 226 million yuan [1] - The company's latest interim performance report shows total operating revenue of 1.805 billion yuan, a year-on-year decrease of 10.20%, and a net profit attributable to shareholders of 221 million yuan, down 7.83% year-on-year [1] Group 2 - The company has a current ratio of 1.561, a quick ratio of 1.385, and a debt-to-asset ratio of 41.44% [1] - Jianmin Pharmaceutical Group Co., Ltd. was established in 1993 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of 153.3986 million yuan [1] - The company has made investments in 30 enterprises and has participated in 5,000 bidding projects, holding 526 trademark registrations and 242 patents [2]